Adverse Drug Reactions and Toxicological Reviews

VOLUME 10 · 1991

Editor: Dr J.P. Griffin, BSc, PhD, FRCP, FRCPath

OXFORD UNIVERSITY PRESS

Oxford University Press, Walton Street, Oxford OX2 6DP
London Glasgow New York Toronto
Delhi Bombay Calcutta Madras Karachi
Kuala Lumpur Singapore Hong Kong Tokyo
Nairobi Dar es Salaam Cape Town
Melbourne Auckland
and associates in
Beirut Berlin Ibadan Mexico City Nicosia

© Oxford University Press 1991
Origination by Meditext, Weybridge, Surrey

Printed in Great Britain by
Henry Ling Ltd., The Dorset Press

Index to Volume 10, 1991
(No. 1 pp 1–76; No. 2 pp 77–123; No. 3 pp 125–188; No. 4 pp 189–236)

ACE (angiotensin-converting enzyme)
  inhibitors, 169–182
  adverse effects
    type A reactions
      angioedema, 174
      cough, 172–173
      hyperkalaemia, 173
      hypotension, 170–171
      renal toxicity, 170
    type B reactions
      dermatological, 176
      gastrointestinal, 176–177
      haematological, 174–175
      neurological, 175–176
      rare, 177–178
      taste disturbances, 176–177
  in pregnancy, 181
  interactions, 181
  in the elderly, 181–182
  metabolic effects
    carbohydrate, 179
    lipids, 179
    uric acid, 179
  overdose, 181
  withdrawal, 180
Adverse reactions (see also Toxicity)
  caused by
    ACE inhibitors, 170–178
    antiarrhythmic drugs, 8–9, 20
    antimalarial drugs, 19
    antimicrobial agents, 8
    aspirin, 17–18
    beta-adrenoreceptor agonists, 5
    beta-adrenoreceptor blockers, 3–4, 40
    calcium-channel blockers, 4
    carbenoxolone, 37–38
    corticosteroids, 5–6
    cyclosporin, 36–37
    diazoxide, 3
    diuretics, 2–3
    erythropoietin, 35–36
    ethanol, 17
    glucorticoids, 38–39
    immunomodulators, 9
    immunosuppressants, 9
    insulin, 11–13
    liquorice, 37–38
    lithium, 7, 21
    mineralocorticoids, 39–40
    NSAIDs, 31–35
    oral contraceptives, 6–7
    pentamidine, 19–20
    phenylpropanolamine, 40
    psychotropic agents, 8
    ritodrine, 20
    somatostatin, 20–21
    sulphonylureas, 14
    trimethoprim, 21
  long latency, monitoring, 209–228
Alcohol causing fetal damage, 80
Alfalfa, toxicity, 195
Amphetamines causing fetal damage, 84
Analgesic abuse causing renal papillary necrosis, 212–213
Angioedema caused by ACE inhibitors, 174
Antiarrhythmic drugs causing
  hyperglycaemia, 8–9
  hypoglycaemia, 20
Antiepileptic agents causing cleft palate, 210
Antimalarial drugs causing hypoglycaemia, 19
Antimicrobial agents causing hyperglycaemia, 8
Aristolochic acid, toxicity, 196
Arsenic, toxicity, 202–204, 210
Aspirin causing hypoglycaemia, 17–18

Babchi, toxicity, 193
Benoxaprofen causing hepatorenal syndrome, 214
Benzodiazepines causing fetal damage, 85
Beta-adrenoreceptor agonists causing hyperglycaemia, 5
Beta-adrenoreceptor blockers causing
  hyperglycaemia, 3–4
  hypertension, 40
Book reviews, 75–76, 119–123, 187–188, 235–236

Caffeine causing fetal damage, 84–85
Calcium-channel blockers causing hyperglycaemia, 4
Captopril — see ACE inhibitors
Carbenoxolone causing hypertension, 37–38
Carbohydrate metabolism
  drug-induced disturbances of, 1–22
    hyperglycaemia, 2–9
    hyperosmolar non-ketotic diabetic coma, 9–10
    hypoglycaemia, 11–21
    lactic acidosis, 10–11
Carcinogenicity studies, sensitivity of, 99–111, 113–118
Ciguatera poisoning, a personal view, 231–234
Cocaine causing fetal damage, 83–84
Coffee enema, toxicity, 197
Comfrey, 47–57
  metabolism of, 49–59
  toxicity, 191–193
    animal, 50–52
    human, 52–56
    mechanism of, 50
  uses of, 47–49

Corticosteroids causing hyperglycaemia, 5–6
Creutzfeldt–Jakob disease, 89–97
  clinical course, 90
  epidemiology, 90–91
  hereditability, 95
  transmission of
    cadaver pituitary glands, human growth hormone from, 91–95
    surgical, 91
Cyclosporin causing hypertension, 36–37

Diazoxide causing hyperglycaemia, 3
Diethylstilboestrol causing transplacental adenocarcinoma of the vagina, 211
Diuretics causing hyperglycaemia, 2–3
Drug development studies, 143–153

Embryotoxicity
  ACE inhibitors, 181
  tests for, 138–1 39
Enzyme-inducing agents causing osteoporosis, 212
Erythropoietin causing hypertension, 35–36
Ethanol causing hypoglycaemia, 17

Fetal damage
  caused by
    alcohol, 80
    amphetamines, 84
    benzodiazepines, 85
    caffeine, 84–85
    cocaine, 83–84
    marijuana, 81–82
    maternal drug addiction, 77–86
    narcotics, 82–83
    tobacco, 78–79
  drug-induced, 210

Ginseng, toxicity, 197
Glucocorticoids causing hypertension, 38–39

Hallucinogenic fungi, toxicity, 197
Henna toxicity, 198
Herbal medicines, adverse reactions, 189–206
Herbal teas, toxicity, 190–193
Honey, rhododendron, toxicity, 198–199
Hyperglycaemia, 2–9, 11–21
  caused by
    antiarrhythmic agents, 8–9
    antimicrobial agents, 8
    beta-adrenoreceptor agonists, 5
    beta-adrenoreceptor blockers, 3–4
    calcium-channel blockers, 4
    corticosteroids, 5–6
    diazoxide, 3
    diuretics, 2–3
    immunomodulators, 9
    immunosuppressants, 9
    lithium, 7
    oral contraceptives, 6–7
    psychotropic agents, 8
Hyperkalaemia caused by ACE inhibitors, 173
Hyperosmolar non-ketotic diabetic coma, 9–10
Hypertension
  caused by
    beta-adrenoceptor blockade, 40
    carbenoxolone, 37–38
    cyclosporin, 36–37
    erythropoietin, 35–36
    glucocorticoids, 38–39
    liquorice, 37–38
    mineralocorticoids, 39–40
    NSAIDs, 31–35
    phenylpropanolamine, 40
  drug-induced, 31–41
  safety of ACE inhibitors in, 169–182
Hypoglycaemia, 11–21
  caused by
    ACE inhibitors, 18–19
    antiarrhythmic drugs, 20
    antimalarial drugs, 19
    aspirin, 17–18
    ethanol, 17
    insulin, 11–13
    lithium, 21
    pentamidine, 19–20
    ritodrine, 20
    somatostatin, 20–21
    sulphonylureas, 14
    trimethoprim–sulphamethoxazole, 21
Hypotension caused by ACE inhibitors, 170–171

Immunomodulators causing hyperglycaemia, 9
Immunosuppressants causing hyperglycaemia, 9
Insulin causing hypoglycaemia, 11–13

Karela, toxicity, 199
Kavakava, toxicity, 193–194
Khat, toxicity, 194

Lactic acidosis, 10–11
Laetrile, toxicity, 199–200
Lead, toxicity, 202–204
Liquorice
  causing hypertension, 37–38
  toxicity, 200–201
Lithium causing
  hyperglycaemia, 7
  hypoglycaemia, 21

Margosa oil, toxicity, 201
Marijuana causing fetal damage, 81–82
Methysergide causing fibrotic syndromes, 213

Mineralocorticoids causing hypertension, 39–40
Mistletoe, toxicity, 201–202
Monitoring adverse drug reactions of long latency, 209–228
  carcinogenesis, 210–212
  detection and monitoring, 216–228
  fetal abnormalities, 210
  non-predictable, 212–214
  predictable, 212

Narcotics causing fetal damage, 82–83
Neuroleptics causing tardive dyskinesia, 213
Nhowa medicines, toxicity, 204–205
NSAIDs causing hypertension, 31–35

Oral contraceptives causing hyperglycaemia, 6–7
Organophosphate poisoning, treatment of, 61–71
Oximes in treatment of organophosphate poisoning, 61–71
  bis-pyridinium oximes, 68–70
  monopyridinium oximes, 66
  obidoxime, 66–68
  pralidoxime salts, 62–66

Pentamidine causing hypoglycaemia, 19–20
Phenylpropanolamine causing hypertension, 40
Practolol causing oculomucocutaneous syndrome, 213–214
Psychotropic agents causing hyperglycaemia, 8
Pyrrolizidine alkaloids, toxicity, 191–193

Red snapper poisoning, a personal view, 231–234
Renal toxicity caused by ACE inhibitors, 170
Reproduction studies, 127–141, 143–153, 161–162
  animal criteria, 130–132
  general criteria, 132–134
  study designs, 134–140, 146–151
Ritodrine causing hypoglycaemia, 20
Rodent neoplasms, spontaneous, 99–111
  incidence of background tumour, 102–104
  statistical considerations, 100–102
  strain comparison, 104–110
  strain selection, 110

Senna, toxicity, 202
Skullcap, toxicity, 195
Somatostatin causing hypoglycaemia, 20–21
Sulphonylureas causing hypoglycaemia, 14

Thornapple, toxicity, 194
Thorotrast causing haemangio-endothelioma of the liver, 212

Tobacco causing fetal damage, 78–79
Toxicity (see also Adverse reactions)
  ACE inhibitors, 171–172, 181
  alfalfa, 195
  alcohol, 80
  amphetamines, 84
  aristolochic acid, 196
  arsenic, 202–204
  babchi, 193
  benzodiazepines, 85
  caffeine, 84–85
  ciguatera, 231–234
  cocaine, 83–84
  coffee enema, 196
  ginseng, 197
  hallucinogenic fungi, 197
  henna, 198
  herbal teas, 190–193
  honey, rhododendron, 198–199
  karela, 199
  kavakava, 193–194
  khat, 194
  laetrile, 199
  lead, 202–204
  liquorice, 200–201
  margosa oil, 201
  marijuana, 81–82
  medicinal products, 127–141, 155–168
  mistletoe, 201
  narcotics, 82–83
  nhowa medicines, 204–205
  oximes, 61–71
  pyrrolizidine alkaloids, 191–193
  red snapper, 231–234
  renal, 170
  reproductive, 127–141, 143–153
  senna, 202
  skullcap, 195
  thornapple, 194
  tobacco, 78–79
  valerian, 195
Toxicity to reproduction and development for pharmaceuticals, proposal for international guidelines on testing, 143–153
Toxicity to reproduction for medicinal products, draft guideline on detection, 127–141
Toxicity studies on medicines, 155–168
  antigenicity, 163–164
  behavioural, 161–162
  carcinogenicity, 159–160
  genotoxicity, 160–161
  human metabolites, 163
  implications, 165–166
  information sources, 156–157
  juvenile, 162–163
  recommendations, 166
  reproductive, 161–162

repeat dose, 159
single dose, 157–159
Trimethoprim–sulphamethoxazole causing hypoglycaemia, 21

Valerian, toxicity, 195

Contents of Volume 10 1991

Spring 1991

Drug-induced disturbances of carbohydrate metabolism

Drug-induced hypertension

Toxicity of comfrey

Toxicology of oximes used in treatment of organophosphate poisoning

Book reviews

Summer 1991

Effects of maternal drug addiction on the fetus

Transmission of Creutzfeldt–Jakob disease by investigation and therapeutic procedures

The use of two compatible rodent strains to improve the sensitivity of carcinogenicity studies. A review of spontaneous rodent neoplasms

When can animal carcinogenicity studies detect a carcinogenic risk? a comment on a paper by M.D.C. Scales and Z.E. Andrews

Book reviews

Autumn 1991

Editorial

Draft guideline on detection of toxicity to reproduction for medicinal products

Proposal for international guidelines for reproductive and developmental toxicity testing for pharmaceuticals

Animal toxicity studies on new medicines and their relationship to clinical exposure: a review of international recommendations

The safety of angiotensin-converting enzyme (ACE) inhibitors in moderate hypertension

Book reviews

Winter 1991

Adverse reactions and interactions with herbal medicines Part 1. Adverse reactions

International monitoring for adverse drug reactions of long latency

Christmas in the Cotswolds: a personal view of red snapper poisoning

Book reviews

Index to Volume 10